AngioDynamics (ANGO) Releases FY13 Earnings Guidance
AngioDynamics (ANGO) issued an update on its FY13 earnings guidance on Thursday morning. The company provided EPS guidance of $0.40-0.42 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.40. The company issued revenue guidance of $355-360 million, compared to the consensus revenue estimate of $360.10 million.
Shares of AngioDynamics (ANGO) traded down 2.10% during mid-day trading on Thursday, hitting $11.18. AngioDynamics (ANGO) has a 52 week low of $10.00 and a 52 week high of $14.80. The stock’s 50-day moving average is currently $10.70. The company’s market cap is $389.1 million.
AngioDynamics last released its earnings data on Thursday, January 3rd. The company reported $0.10 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.09 by $0.01. The company had revenue of $87.00 million for the quarter, compared to the consensus estimate of $87.40 million. During the same quarter in 2012, the company posted $0.13 earnings per share. The company’s quarterly revenue was up 49.7% on a year-over-year basis. AngioDynamics has set its FY13 guidance at $0.40-0.42 EPS. Analysts expect that AngioDynamics (ANGO) will post $0.40 EPS for the current fiscal year.
ANGO has been the subject of a number of recent research reports. Analysts at Zacks reiterated a neutral rating on shares of AngioDynamics in a research note to investors on Thursday, November 1st. They now have a $11.00 price target on the stock. Analysts at Canaccord Genuity cut their price target on shares of AngioDynamics from $14.00 to $13.50 in a research note to investors on Tuesday, October 9th. They now have a hold rating on the stock.
AngioDynamics, Inc. (AngioDynamics) is a provider of medical devices used in minimally invasive, image-guided procedures to treat peripheral vascular disease (PVD) and local oncology therapy options for treating cancer, including radiofrequency ablation (RFA) systems, NanoKnife Ablation Systems, surgical resection systems and embolization products for treating benign and malignant tumors.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.